Oura Just Made the Boldest Femtech Bet of 2026 — And It's Built on AI

Oura , the Finnish-American smart ring company that has spent the past decade building one of the most precise consumer biometric platforms in the market, is making its biggest expansion into hormonal health to date. On May 6, the company is rolling out two new features globally to Oura Ring Gen3 and Oura Ring 4 members: Hormonal Birth Control support in Cycle Insights, and Menopause Insights built around a proprietary clinically-validated questionnaire. Together, these features mark what the company is positioning as a step-change in how femtech is built — moving beyond symptom logging into a system that connects subjective experience with continuous biometric data, layered on top of a proprietary women's health AI model Oura has been quietly developing. For enterprise AI watchers tracking healthcare deployments , this is one of the cleaner examples in 2026 of consumer AI moving into clinically meaningful territory — not as a chatbot wrapper, but as a multimodal system combining sensor data, validated clinical instruments, and same-day care delivery. What's actually launching The two features address two of the most under-served stages in women's health. Hormonal Birth Control support integrates directly into Oura's existing Cycle Insights feature, adapting its tracking model to over 20 unique combinations of hormonal birth control methods — pills, patches, IUDs, implants, and more. More than 300 million women globally use hormonal birth control, and Oura's pitch is that members can now see how their specific contraceptive choice shapes their temperature, sleep, recovery, bleeding, and symptoms over time. The U.S. rollout adds a partnership with Twentyeight Health , letting members move from insight to same-day, insurance-enabled care with licensed clinicians directly inside the Oura App. That insight-to-action loop is unusual for consumer wearables, which typically stop at data presentation and leave the care navigation to the user. Menopause Insights is the more ambitious launch. At its core sits the Menopause Impact Scale (MIS) — a proprietary, research-backed questionnaire developed by Oura that measures menopause's impact on quality of life and daily functioning across 22 symptoms. Unlike traditional menopause screening tools that produce a single score, the MIS generates personalized, on-demand explanations of results, grounded in both questionnaire responses and longitudinal biometric data from the ring. The system shows how symptoms correlate with physiological trends — heart rate variability, sleep disturbances — and lets members track the long-term impact of lifestyle adjustments like sleep hygiene changes, medication, or stress management. The output is a shareable dashboard members can take into clinical conversations. Why the architecture matters Holly Shelton , Oura's Chief Product Officer, framed the underlying logic in the company announcement: by connecting hormonal context to the biometric data Oura already tracks, the company is giving women visibility, language, and evidence at a scale that has not previously existed. The technical architecture deserves attention because it reflects where serious health AI is heading. First, continuous biometric sensing . Oura's ring has been collecting high-fidelity sleep, temperature, heart rate, and HRV data from members for years — generating one of the largest longitudinal women's health datasets outside of formal clinical trials. That data depth is the substrate. Second, a proprietary women's health AI model . Oura has been building this model alongside its general health features, and these new launches sit on top of it. The model is what allows the system to adapt cycle tracking to 20+ birth control methods, generate personalized explanations of MIS results, and surface meaningful patterns across hormonal life stages. Third, clinically-validated instruments . The MIS is presented as research-backed and developed by Oura — meaning the company has done the work to validate the questionnaire against clinical standards before deploying it. This matters enormously for credibility in healthcare. Wellness apps that ship un-validated screening tools tend to attract regulatory scrutiny and clinician skepticism. Oura is positioning itself the other way. Fourth, insight-to-action workflows . The Twentyeight Health partnership in the U.S. is the operational layer. Generating an insight is one thing; routing the user to a licensed clinician who can prescribe within the same app is qualitatively different. This stack — continuous data plus AI model plus validated clinical instrument plus integrated care delivery — is becoming the template for serious consumer health AI in 2026, a pattern visible across the broader enterprise AI buildout in regulated verticals . The femtech market context The global femtech market has been growing at double-digit rates, but most of the growth has been concentrated at the symptom-logging and education layer. Real clinical integ

Oura Just Made the Boldest Femtech Bet of 2026 — And It's Built on AI

What's actually launching

Keep reading. It's free.

Related stories